• PMST Training Site Self-Assessment Form

    This form must be completed by potential and existing training sites as part of our ongoing quality management of the PMST programme.

  • Training site and point of contact

  • Why are you completing this form?*

  • Pharmaceutical medicine trainees

  • Approved educational supervisors and associate educational supervisors

  • Training locations

    Please list the training site's locations that pharmaceutical medicine trainees can rotate.

  • Standards of quality

  • 1. Learning environment and culture

  • 1.1 Pharmaceutical medicine trainees are in an environment that delivers safe, effective, compassionate care that provides a positive experience for service users.
  • 0/100
  • 1.2 The learning environment is one in which education and training is valued and pharmaceutical medicine trainees are treated fairly, with dignity and respect, and are not subject to negative attitudes or behaviour.
  • 0/100
  • 1.3 There are opportunities for pharmaceutical medicine trainees to be involved in activities that facilitate quality improvement (QI), improving evidence-based practice (EBP) and research and innovation (R&I).
  • 0/100
  • 1.4 There are opportunities to learn constructively from the experience and outcomes of service users, whether positive or negative.
  • 0/100
  • 1.5 The learning environment provides suitable educational facilities for both pharmaceutical medicine trainees, educational supervisors and associate educational supervisors, including space, IT facilities and access to quality assured library and knowledge.
  • 0/100
  • 1.6 The learning environment promotes inter-professional learning opportunities.
  • 0/100

  • 2. Educational governance and leadership

  • 2.1 The educational governance arrangements measure performance against the quality standards and actively respond when standards are not being met.
  • 0/100
  • 2.2 The educational leadership uses the educational governance arrangements to continuously improve the quality of education and training.
  • 0/100
  • 2.3 The educational governance structures promote team-working and a multi-professional approach to education and training where appropriate, through multi-professional educational leadership.
  • 0/100
  • 2.4 Education and training opportunities are based on principles of equality and diversity.
  • 0/100
  • 2.5 There are processes in place to inform the appropriate stakeholders when performance issues with pharmaceutical medicine trainees are identified or pharmaceutical medicine trainees are involved in patient safety incidents.
  • 0/100

  • 3. Supporting and empowering pharmaceutical medicine trainees

  • 3.1 Pharmaceutical medicine trainees receive educational and pastoral support to be able to demonstrate what is expected in their curriculum or professional standards to achieve the learning outcomes.
  • 0/100
  • 3.2 Pharmaceutical medicine trainees are supported to complete appropriate summative and formative assessments to evidence that they are meeting their curriculum, professional standards or learning outcomes.
  • 0/100
  • 3.3 Pharmaceutical medicine trainees feel they are valued members of the healthcare team within which they are placed.
  • 0/100
  • 3.4 Pharmaceutical medicine trainees receive an appropriate and timely induction into the learning environment.
  • 0/100
  • 3.5 Pharmaceutical medicine trainees understand their role and the context of their placement in relation to care pathways and patient pathways.
  • 0/100

  • 4. Supporting and empowering educational and associate educational supervisors

  • 4.1 Those undertaking formal education and training roles are appropriately trained as defined by the relevant regulator or professional body.
  • 0/100
  • 4.2 Educational supervisors and associate educational supervisors are familiar with the 2021 PMST curriculum.
  • 0/100
  • 4.3 Educational supervisor and associate educational supervisor performance and progress is reviewed through appraisals and other appropriate mechanisms, with constructive feedback and support provided for role development and progression. Educational Supervisors are recognised and re-listed by the GMC every 4 years.
  • 0/100
  • 4.4 Formally recognised educational supervisors and associate educational supervisors are appropriately supported to undertake their roles.
  • 0/100

  • Declaration

    The declaration must be signed by the point of contact (e.g. medical director, director of manager of human resources or training department or administrator/manager responsible for managing the training site's delivery of the PMST programme).

  • I declare on behalf of my organisation that:

    i) the information entered on this PMST training site self-assessment form is accurate and true to the best of our knowledge;

    ii) we understand the requirements of the ‘Curriculum for Pharmaceutical Medicine Specialty Training’ (August 2021); 


    iii) we fully support the delivery of the Pharmaceutical Medicine Specialty Training (PMST) as defined by the 2021 PMST curriculum;


    iv) we have read and understand our responsibilities as a GMC-approved training site as detailed in the GMC’s ‘Promoting excellence: standards for medical education and training’ and we will meet/work towards meeting our responsibilities and the standards detailed in ‘Promoting excellence’;

    v) we will participate in and engage with all GMC quality assurance and FPM/Pharmaceutical Medicine Deanery quality management activities that relate to the delivery of the PMST programme such as supporting pharmaceutical medicine trainees and educational supervisors;

    vi) we understand that FPM and the deanery may ask the GMC to remove approval of our organisation for administrative reasons (e.g. the organisation is dissolved, merges with another organisation, no longer has any pharmaceutical medicine trainees) as well as not meeting GMC standards and the requirements of the PMST programme;

    vii) we will update FPM and the deanery if our point of contact changes; and

    viii) we will update FPM and the deanery if our organisation’s business address or business name changes or we merge with another organisation and our status as a separate legal entity changes.

  • Date*
     - -
    2 digit day, 2 digit month, 4 digit year

  • Declaration

    The declaration must be signed by the point of contact (e.g. medical director, director of manager of human resources or training department or administrator/manager responsible for managing the training site's delivery of the PMST programme).

  • I declare on behalf of my organisation that we have decided to relinquish our status as a training site for the PMST programme in full knowledge that:

    • FPM will ask the GMC to remove us from its list of training sites for the PMST programme;
    • we must inform pharmaceutical physicians employed by us and who want to undertake PMST that they must postpone submitting a PMST application until we become a training site;
    • we must re-apply to FPM to become a training site before we can support a pharmaceutical physician employed by us to undertake PMST; and
    • we may have to participate in an assessment process to determine our suitability to become a training site before FPM decides to apply to the GMC to approve us as a training site.
  • Date
     - -
    2 digit day, 2 digit month, 4 digit year
  • Should be Empty: